Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135)
(me NIN joe kok al pol i SAK a ride vak SEEN groops aye, see, why & dubl yoo won thur tee fyve)
- Meningococcal Polysacc Vaccine A/C/Y/W-135
- Meningococcal Polysaccharide Vaccine
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Injection, powder for reconstitution [MPSV4]:
Menomune-A/C/Y/W-135: 50 mcg each of polysaccharide antigen groups A, C, Y, and W-135 per 0.5 mL dose [contains lactose 2.5-5 mg/0.5 mL, natural rubber/natural latex in packaging, thimerosal in diluent for multidose vial]
Brand Names: U.S.
- Vaccine, Inactivated (Bacterial)
Induces the formation of bactericidal antibodies to meningococcal antigens; the presence of these antibodies is strongly correlated with immunity to meningococcal disease caused by Neisseria meningitidis groups A, C, Y and W-135.
Onset of Action
Antibody levels: 7-10 days
Duration of Action
Antibodies against group A and C polysaccharides decline markedly (to prevaccination levels) over the first 3 years following a single dose of vaccine, especially in children <4 years of age
Use: Labeled Indications
Meningococcal disease prevention: Active immunization of patients 2 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.
The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for persons at increased risk for meningococcal disease. Meningococcal quadrivalent conjugate vaccine (MenACWY; Menactra, Menveo) is preferred; meningococcal polysaccharide vaccine (MPSV4; Menomune) is preferred in meningococcal vaccine-naive adults ≥56 years of age requiring only a single vaccination (CDC/ACIP [Cohn 2013]).
Those at increased risk of meningococcal disease include the following:
- Persons ≥2 months of age with medical conditions such as anatomical or functional asplenia or persistent compliment component deficiencies (eg, C5-C9, properdin, factor H, or factor D)
- Persons ≥9 months of age that travel to or reside in countries where meningococcal disease is hyperendemic or epidemic, especially if contact with the local population will be prolonged
- Unvaccinated or incompletely vaccinated first year college students living in residence halls
- Military recruits
- Microbiologists with occupational exposure
- Persons (in all recommended age groups) at risk who are part of outbreaks caused by vaccine preventable serogroups
Hypersensitivity to any component of the formulation
Immunization: SubQ: 0.5 mL/dose
ACIP recommendations (CDC/ACIP [Cohn 2013]):
Adults <56 years: Not routinely recommended.
Adults ≥56 years: Meningococcal polysaccharide vaccine (MPSV4,Menomune) is preferred for meningococcal vaccine-naive persons in this age group who are at increased risk of meningococcal infection and require a single dose (eg, travelers or during a community outbreak). Persons previously vaccinated with a quadrivalent meningococcal conjugate vaccine (MenACWY, Menveo, or Menactra) and who require revaccination or for whom multiple doses are anticipated, MenACWY-D (Menactra) is preferred (eg, persons with asplenia or microbiologists).
Refer to adult dosing.
Immunization: Children ≥2 years and Adolescents: SubQ: 0.5 mL/dose
ACIP recommendations (CDC/ACIP [Cohn 2013]): Children and Adolescents: Not routinely recommended.
Dosing: Renal Impairment
There are no dosage adjustments provided in manufacturer’s labeling.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in manufacturer’s labeling.
Reconstitute using provided diluent; shake well. Use single-dose vial immediately after reconstitution. Use multidose vial within 35 days of reconstitution.
Administer by SubQ injection to the deltoid region; do not administer intradermally, IM, or IV. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (NCIRD/ACIP 2011). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.
Do not mix with other vaccines or injections. Separate needles and syringes should be used for each injection.
Prior to and following reconstitution, store vaccine and diluent at 2°C to 8°C (35°F to 46°F); do not freeze.
Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy. Consider therapy modification
Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation. Consider therapy modification
Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Exceptions: Cytarabine (Liposomal). Consider therapy modification
Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated). Monitor therapy
Central nervous system: Headache (29% to 42%), fatigue (children ≥11 years, adolescents, and adults: 25% to 32%), malaise (children ≥11 years, adolescents, and adults: 17% to 22%), irritability (children 2 to 10 years: 12%), drowsiness (children 2 to 10 years: 11%)
Gastrointestinal: Diarrhea (10% to 14%)
Local: Pain at injection site (adults: 48%; children and adolescents 2 to 18 years: 26% to 29%), erythema at injection site (adults: 16%; children and adolescents 2 to 18 years: 6% to 8%), induration at injection site (4% to 11%)
Neuromuscular & skeletal: Arthralgia (adults: 16%; children and adolescents 2 to 18 years: 5% to 10%)
1% to 10%:
Central nervous system: Chills (children ≥11 years, adolescents, and adults: 4% to 6%)
Dermatologic: Skin rash (children and adolescents 2 to 18 years: 1% to 3%; adults: <1%)
Gastrointestinal: Anorexia (8% to 10%), vomiting (1% to 3%)
Local: Swelling at injection site (3% to 8%)
Miscellaneous: Fever (children and adolescents 2 to 18 years: 3% to 5%; adults: <1%)
Postmarketing and/or case reports: Guillain-Barré syndrome, hypersensitivity (angioedema, dyspnea, pruritus, rash, urticaria), vasodepressor syncope
Concerns related to adverse effects:
• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (NCIRD/ACIP 2011).
• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (NCIRD/ACIP 2011).
• Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Consider deferring administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever).
• Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against N. meningitidis serogroup B.
Concurrent drug therapy issues:
• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, >1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (NCIRD/ACIP 2011).
• Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines (IDSA [Rubin 2014]; NCIRD/ACIP 2011); inactivated vaccines should be administered ≥2 weeks prior to planned immunosuppression when feasible (IDSA [Rubin 2014]).
Dosage form specific issues:
• Latex: Packaging may contain natural latex rubber.
• Thimerosal: Some dosage forms contain thimerosal.
• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (NCIRD/ACIP 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).
• Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Adult Immunization Schedule (ACIP [Kim 2016]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cerebrospinal fluid leaks, cochlear implants, or sickle cell disease are available from the IDSA (Rubin 2014).
• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (NCIRD/ACIP 2011).
Monitor for syncope for 15 minutes following administration (NCIRD/ACIP 2011). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.
Pregnancy Risk Factor
Animal reproduction studies have not been conducted. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (NCIRD/ACIP 2011). Pregnancy should not preclude vaccination if indicated (CDC/ACIP [Cohn 2013]).
More about meningococcal polysaccharide vaccine
- Other brands: Menomune A/C/Y/W-135